Biocept Announces Pricing of $2.5 Million Registered Direct Offering Priced at Market
Under the terms of the purchase agreement,
The gross proceeds to
The shares of common stock and pre-funded warrants are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-224946), which was declared effective by the
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the shares of common stock and pre-funded warrants will be filed by
About
Forward-Looking Statements Disclaimer Statement
This press release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to close the offering and the gross proceeds from the offering, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Investor Contact: |
Media Contact: |
LHA Investor Relations |
Trevelino/Keller |
Jody Cain |
Colleen Murphy |
310-691-7100 |
404-214-0722, Ext. 109 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-announces-pricing-of-2-5-million-registered-direct-offering-priced-at-market-300716641.html
SOURCE